The Europe molecular diagnostics market is expected to grow from US$ 4,592.54 million in 2022 to US$ 11,225.77 million by 2030. It is estimated to grow at a CAGR of 11.8% from 2022 to 2030.
Chronic diseases such as chronic obstructive pulmonary disease (COPD), diabetes, cancer, and arthritis can be life-threatening if left untreated. For instance, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Germany. According to the Deutsches Ärzteblatt, the prevalence of CLL in Germany stands at ~6 cases per 100,000; nearly 850 women and 1,000 men die from CLL every year.
Based on disease area, the Europe molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest Europe molecular diagnostics market share in 2022.
Based on technology, the Europe molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest Europe molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.
Based on product and services, the Europe molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest Europe molecular diagnostics market share in 2022.
Based on end users, the Europe molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest Europe molecular diagnostics market share in 2022.
Based on country, the Europe molecular diagnostics market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe molecular diagnostics market in 2022.
Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, and Novartis AG are some of the leading companies operating in the Europe molecular diagnostics market.
Reasons to Buy
Surging Prevalence of Associated Diseases Fuels Europe Molecular Diagnostics Market
Molecular diagnostics procedures can be employed in the detection of a wide range of conditions such as oncologic diseases, infectious diseases, cardiac diseases, and immune system disorders; they can also be used in genetic testing using genetic material such as DNA and RNA for the diagnosis of different diseases. Cancer is one of the leading causes of death worldwide. The early detection of the disease can help prevent death among the patients. According to the data published by the UK.GOV on November 22, 2021, the infection rate of COVID-19 was ~422.7 per 100,000 population. Thus, the rising prevalence of target diseases fuels the molecular diagnostics market growth.Europe Molecular Diagnostics Market Overview
The European molecular diagnostics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant share of the global molecular diagnostics market and is expected to register a robust CAGR during 2022-2030. The market growth in Europe is attributed to growing life science research and an increase in government investment in testing infectious diseases.Chronic diseases such as chronic obstructive pulmonary disease (COPD), diabetes, cancer, and arthritis can be life-threatening if left untreated. For instance, chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Germany. According to the Deutsches Ärzteblatt, the prevalence of CLL in Germany stands at ~6 cases per 100,000; nearly 850 women and 1,000 men die from CLL every year.
Europe Molecular Diagnostics Market Revenue and Forecast to 2030 (US$ Million)
Europe Molecular Diagnostics Market Segmentation
The Europe molecular diagnostics market is segmented into disease area, technology, product and services, end user, and country.Based on disease area, the Europe molecular diagnostics market is segmented into infectious disease, oncology, genetic testing, cardiac diseases, immune system disorders, and others. The infectious disease segment registered the largest Europe molecular diagnostics market share in 2022.
Based on technology, the Europe molecular diagnostics market is segmented into polymerase chain reaction (PCR), in situ hybridization, isothermal nucleic acid amplification technology (INAAT), DNA sequencing and next-generation sequencing (NGS), DNA microarrays, and others. The polymerase chain reaction (PCR) segment registered the largest Europe molecular diagnostics market share in 2022. The polymerase chain reaction (PCR) is further sub segmented into RT-PCR, qPCR, multiplex PCR, and others.
Based on product and services, the Europe molecular diagnostics market is segmented into assays and kits, instruments, and services and software. The assays and kits segment registered the largest Europe molecular diagnostics market share in 2022.
Based on end users, the Europe molecular diagnostics market is segmented into diagnostic laboratories, hospitals and clinics, research and academic institutes, and others. The diagnostic laboratories segment held the largest Europe molecular diagnostics market share in 2022.
Based on country, the Europe molecular diagnostics market has been categorized into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe molecular diagnostics market in 2022.
Abbott Laboratories, Agilent Technologies Inc, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Qiagen NV, bioMerieux SA, Illumina Inc, Danaher, Siemens Healthineers AG, and Novartis AG are some of the leading companies operating in the Europe molecular diagnostics market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe molecular diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe molecular diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the molecular diagnostics market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Molecular Diagnostics Market Landscape
5. Europe Molecular Diagnostics Market - Key Industry Dynamics
6. Molecular Diagnostics Market - Europe Market Analysis
7. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Disease Area
8. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Technology
9. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by Product and Services
10. Europe Molecular Diagnostics Market - Revenue and Forecast to 2030 - by End User
11. Europe Molecular Diagnostics Market - Country Analysis
12. Europe Molecular Diagnostics Market Industry Landscape
13. Europe Molecular Diagnostics Market, Key Company Profiles
14. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Agilent Technologies Inc
- bioMerieux SA
- Danaher
- F. Hoffmann-La Roche Ltd
- Illumina Inc
- Novartis AG
- Qiagen NV
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc
